CliffBio
small molecule

DYANAVEL XR

AMPHETAMINE; AMPHETAMINE ASPARTATE/DEXTROAMPHETAMINE SULFATE

Loss of exclusivitySeptember 2036latest FDA-listed patent expiry
CompanyTris. →View the full company profile on CliffBio

Drug detail

Brand nameDYANAVEL XR
Active ingredientAMPHETAMINE; AMPHETAMINE ASPARTATE/DEXTROAMPHETAMINE SULFATE
Strength2MG/ML;EQ 0.5MG BASE/ML
Dosage formSUSPENSION, EXTENDED RELEASE
RouteORAL
ModalitySmall molecule
FDA approvalOctober 2015
Marketing statusRX

Listed patents

PatentExpiresType
11590228September 2036product
8062667March 2029product
8597684March 2027product
10086087March 2027product
8747902March 2027product
8883217March 2027product
9675703March 2027product

More from Tris.

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

DYANAVEL XR patent cliff — loss of exclusivity September 2036 | CliffBio